Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer
Treatment options for patients with pancreatic cancer are limited and survival prospects have barely changed over the past 4 decades. Chemoradiation treatment (CRT) has been used as neoadjuvant therapy in patients with borderline resectable disease to reduce tumour burden and increase the proportion...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2021
|
| _version_ | 1797107341775077376 |
|---|---|
| author | Browning, RJ Able, S Ruan, J-L Bau, L Allen, PD Kersemans, V Wallington, S Kinchesh, P Smart, S Kartsonaki, C Kamila, S Logan, K Taylor, MA McHale, AP Callan, JF Stride, E Vallis, KA |
| author_facet | Browning, RJ Able, S Ruan, J-L Bau, L Allen, PD Kersemans, V Wallington, S Kinchesh, P Smart, S Kartsonaki, C Kamila, S Logan, K Taylor, MA McHale, AP Callan, JF Stride, E Vallis, KA |
| author_sort | Browning, RJ |
| collection | OXFORD |
| description | Treatment options for patients with pancreatic cancer are limited and survival prospects have barely changed over the past 4 decades. Chemoradiation treatment (CRT) has been used as neoadjuvant therapy in patients with borderline resectable disease to reduce tumour burden and increase the proportion of patients eligible for surgery. Antimetabolite drugs such as gemcitabine and 5-fluorouracil are known to sensitise pancreatic tumours to radiation treatment. Likewise, photodynamic therapy (PDT) has also been shown to enhance the effect of radiation therapy. However, PDT is limited to treating superficial lesions due to the attenuation of light by tissue. The ability of the related technique, sonodynamic therapy (SDT), to enhance CRT was investigated in two murine models of pancreatic cancer (PSN-1 and BxPC-3) in this study. SDT uses low intensity ultrasound to activate an otherwise non-toxic sensitiser, generating toxic levels of reactive oxygen species (ROS) locally. It is applicable to greater target depths than PDT due to the ability of ultrasound to propagate further than light in tissue. Both CRT and the combination of CRT plus SDT delayed tumour growth in the two tumour models. In the PSN-1 model, but not the BxPC-3 model, the combination treatment caused an increase in survival relative to CRT alone (p = 0.038). The improvement in survival conferred by the addition of SDT in this model may be related to differences in tumour architecture between the two models. MRI and US images showed that PSN-1 tumours were less well perfused and vascularised than BxPC-3 tumours. This poor vascularisation may explain why PSN-1 tumours were more susceptible to the effects of vascular damage exerted by SDT treatment.
|
| first_indexed | 2024-03-07T07:13:13Z |
| format | Journal article |
| id | oxford-uuid:09187a5c-c713-4534-b5d7-3cd0f933112d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:13:13Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:09187a5c-c713-4534-b5d7-3cd0f933112d2022-07-26T09:04:45ZCombining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:09187a5c-c713-4534-b5d7-3cd0f933112dEnglishSymplectic ElementsElsevier2021Browning, RJAble, SRuan, J-LBau, LAllen, PDKersemans, VWallington, SKinchesh, PSmart, SKartsonaki, CKamila, SLogan, KTaylor, MAMcHale, APCallan, JFStride, EVallis, KATreatment options for patients with pancreatic cancer are limited and survival prospects have barely changed over the past 4 decades. Chemoradiation treatment (CRT) has been used as neoadjuvant therapy in patients with borderline resectable disease to reduce tumour burden and increase the proportion of patients eligible for surgery. Antimetabolite drugs such as gemcitabine and 5-fluorouracil are known to sensitise pancreatic tumours to radiation treatment. Likewise, photodynamic therapy (PDT) has also been shown to enhance the effect of radiation therapy. However, PDT is limited to treating superficial lesions due to the attenuation of light by tissue. The ability of the related technique, sonodynamic therapy (SDT), to enhance CRT was investigated in two murine models of pancreatic cancer (PSN-1 and BxPC-3) in this study. SDT uses low intensity ultrasound to activate an otherwise non-toxic sensitiser, generating toxic levels of reactive oxygen species (ROS) locally. It is applicable to greater target depths than PDT due to the ability of ultrasound to propagate further than light in tissue. Both CRT and the combination of CRT plus SDT delayed tumour growth in the two tumour models. In the PSN-1 model, but not the BxPC-3 model, the combination treatment caused an increase in survival relative to CRT alone (p = 0.038). The improvement in survival conferred by the addition of SDT in this model may be related to differences in tumour architecture between the two models. MRI and US images showed that PSN-1 tumours were less well perfused and vascularised than BxPC-3 tumours. This poor vascularisation may explain why PSN-1 tumours were more susceptible to the effects of vascular damage exerted by SDT treatment. |
| spellingShingle | Browning, RJ Able, S Ruan, J-L Bau, L Allen, PD Kersemans, V Wallington, S Kinchesh, P Smart, S Kartsonaki, C Kamila, S Logan, K Taylor, MA McHale, AP Callan, JF Stride, E Vallis, KA Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer |
| title | Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer |
| title_full | Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer |
| title_fullStr | Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer |
| title_full_unstemmed | Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer |
| title_short | Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer |
| title_sort | combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer |
| work_keys_str_mv | AT browningrj combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT ables combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT ruanjl combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT baul combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT allenpd combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT kersemansv combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT wallingtons combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT kincheshp combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT smarts combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT kartsonakic combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT kamilas combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT logank combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT taylorma combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT mchaleap combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT callanjf combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT stridee combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer AT valliska combiningsonodynamictherapywithchemoradiationforthetreatmentofpancreaticcancer |